Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients.
作者信息
Sklavenitis-Pistofidis Romanos, Capelletti Marzia, Liu Chia-Jen, Reidy Mairead, Zavidij Oksana, Huynh Daisy, Henrick Patrick, Savell Alexandra, Reyes Kaitlen, Rivotto Bradley, Bustoros Mark, Perilla-Glen Adriana, Trippa Lorenzo, Castillo Jorge J, Treon Steven P, Ghobrial Irene M
机构信息
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and.
Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA.
出版信息
Blood. 2018 Dec 13;132(24):2608-2612. doi: 10.1182/blood-2018-07-863241. Epub 2018 Oct 26.
Abstract
摘要
相似文献
1
Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients.
Blood. 2018 Dec 13;132(24):2608-2612. doi: 10.1182/blood-2018-07-863241. Epub 2018 Oct 26.
2
CXCR4 mutational status does not impact outcomes in patients with Waldenström macroglobulinemia treated with proteasome inhibitors.
Am J Hematol. 2020 Apr;95(4):E95-E98. doi: 10.1002/ajh.25730. Epub 2020 Jan 23.
3
Genomic Landscape of CXCR4 Mutations in Waldenström Macroglobulinemia.
Clin Cancer Res. 2016 Mar 15;22(6):1480-8. doi: 10.1158/1078-0432.CCR-15-0646. Epub 2015 Oct 21.
4
TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenström macroglobulinaemia.
Br J Haematol. 2019 Jan;184(2):242-245. doi: 10.1111/bjh.15560. Epub 2018 Sep 5.
5
clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemia.
Blood Adv. 2019 Oct 8;3(19):2800-2803. doi: 10.1182/bloodadvances.2019000635.
6
Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia.
Blood. 2014 May 1;123(18):2791-6. doi: 10.1182/blood-2014-01-550905. Epub 2014 Feb 19.
7
CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: A systematic review.
Expert Rev Hematol. 2019 Oct;12(10):873-881. doi: 10.1080/17474086.2019.1649132. Epub 2019 Jul 30.
8
Waldenstrom macroglobulinemia: genetics dictates clinical course.
Blood. 2014 May 1;123(18):2750-1. doi: 10.1182/blood-2014-03-558973.
9
CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib.
Br J Haematol. 2019 Nov;187(3):356-363. doi: 10.1111/bjh.16088. Epub 2019 Jul 3.
10
Pattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance.
Haematologica. 2017 Dec;102(12):2077-2085. doi: 10.3324/haematol.2017.172718. Epub 2017 Oct 5.
引用本文的文献
1
Bortezomib, Rituximab and Dexamethasone Regimen (BDR) in Waldenström Macroglobulinaemia: A Retrospective Real-World Analysis.
EJHaem. 2025 Mar 19;6(2):e70019. doi: 10.1002/jha2.70019. eCollection 2025 Apr.
2
Single-cell RNA sequencing defines distinct disease subtypes and reveals hypo-responsiveness to interferon in asymptomatic Waldenstrom's Macroglobulinemia.
Nat Commun. 2025 Feb 10;16(1):1480. doi: 10.1038/s41467-025-56323-w.
3
Current approach to Waldenström macroglobulinemia.
Blood Rev. 2023 Nov;62:101129. doi: 10.1016/j.blre.2023.101129. Epub 2023 Aug 26.
4
Ibrutinib in relapsed/refractory patients with Waldenström macroglobulinemia: a real-life, retrospective study on behalf of the "RTL" (regional Tuscan lymphoma network).
Ann Hematol. 2023 Apr;102(4):841-849. doi: 10.1007/s00277-023-05113-9. Epub 2023 Feb 3.
5
Zanubrutinib in Treating Waldenström Macroglobulinemia, the Last Shall Be the First.
Ther Clin Risk Manag. 2022 Jun 23;18:657-668. doi: 10.2147/TCRM.S338655. eCollection 2022.
6
Treatment paradigm in Waldenström macroglobulinemia: frontline therapy and beyond.
Ther Adv Hematol. 2022 Apr 29;13:20406207221093962. doi: 10.1177/20406207221093962. eCollection 2022.
7
Waldenström's macroglobulinemia front line treatment.
Hemasphere. 2019 Jun 30;3(Suppl). doi: 10.1097/HS9.0000000000000222. eCollection 2019 Jun.
8
Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study.
J Clin Oncol. 2022 Jan 1;40(1):40-51. doi: 10.1200/JCO.21.00105. Epub 2021 Aug 13.
9
CXCR4 in Waldenström's Macroglobulinema: chances and challenges.
Leukemia. 2021 Feb;35(2):333-345. doi: 10.1038/s41375-020-01102-3. Epub 2020 Dec 3.
10
Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up.
Blood Adv. 2020 Aug 25;4(16):3952-3959. doi: 10.1182/bloodadvances.2020001963.
本文引用的文献
1
Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia.
N Engl J Med. 2018 Jun 21;378(25):2399-2410. doi: 10.1056/NEJMoa1802917. Epub 2018 Jun 1.
2
Prospective Clinical Trial of Ixazomib, Dexamethasone, and Rituximab as Primary Therapy in Waldenström Macroglobulinemia.
Clin Cancer Res. 2018 Jul 15;24(14):3247-3252. doi: 10.1158/1078-0432.CCR-18-0152. Epub 2018 Apr 16.
3
Using high-sensitivity sequencing for the detection of mutations in BTK and PLCγ2 genes in cellular and cell-free DNA and correlation with progression in patients treated with BTK inhibitors.
Oncotarget. 2017 Mar 14;8(11):17936-17944. doi: 10.18632/oncotarget.15316.
4
Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016.
JAMA Oncol. 2017 Sep 1;3(9):1257-1265. doi: 10.1001/jamaoncol.2016.5763.
5
Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214).
Clin Cancer Res. 2017 May 15;23(10):2400-2404. doi: 10.1158/1078-0432.CCR-16-1918. Epub 2016 Nov 11.
6
Clinical Validation of a CXCR4 Mutation Screening Assay for Waldenstrom Macroglobulinemia.
Clin Lymphoma Myeloma Leuk. 2016 Jul;16(7):395-403.e1. doi: 10.1016/j.clml.2016.04.014. Epub 2016 May 5.
7
Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia.
Br J Haematol. 2016 Mar;172(5):735-44. doi: 10.1111/bjh.13897. Epub 2015 Dec 13.
8
Genomic Landscape of CXCR4 Mutations in Waldenström Macroglobulinemia.
Clin Cancer Res. 2016 Mar 15;22(6):1480-8. doi: 10.1158/1078-0432.CCR-15-0646. Epub 2015 Oct 21.
9
ROS-Induced CXCR4 Signaling Regulates Mantle Cell Lymphoma (MCL) Cell Survival and Drug Resistance in the Bone Marrow Microenvironment via Autophagy.
Clin Cancer Res. 2016 Jan 1;22(1):187-99. doi: 10.1158/1078-0432.CCR-15-0987. Epub 2015 Sep 8.
10
Ibrutinib in previously treated Waldenström's macroglobulinemia.
N Engl J Med. 2015 Apr 9;372(15):1430-40. doi: 10.1056/NEJMoa1501548.
Zotero 插件